The trial used Cannabidiol throughout a three-week course of treatment for Covid-19 sufferers at the hospital’s ICU unit. The clinic’s head of intensive care medicine, Rudolf Likar, began by administering a 200-milligram dose of CBD each day, later increasing the dose to 300 milligrams. “We have seen that the inflammation parameters in the blood go down, and people leave the hospital faster than the comparison group,” Likar said. “CBD supports the immune system,” he revealed.

As noted in a local Austrian newspaper, Likar believes that CBD’s cannabidiol closes off the ACE2 receptor through which SARS-CoV-2 enters human cells and then self-replicates. The clinical trial suggests that the inflammatory effects found in CBD oil can be even more beneficial compared to other commonly-used drugs due to cannabidiol’s ability to cross the blood-brain barrier and avert some of the more extreme neurological damage that stems from long-term Covid-19 infections.